Experimental Cancer Therapeutics Unit (ECRU)

The Experimental Cancer Therapeutics Unit (ECRU) was set up with the purpose of academically enhancing support for early phase clinical trials. Its focus is on providing a single point of engagement for the conduct of Phase 0/1/2 trials. The unit is part of the Division of Medical Oncology and was initiated in 2009. The core team collaborates closely with other clinicians and scientists committed to preclinical and clinical development of new anticancer drugs. Our core interests cover all types of cancer. Our therapeutic modalities include antibody–drug conjugates (ADCs), small molecules, bispecifics, CAR T-cell therapies, cell and gene therapies, oncolytic viruses, radiopharmaceuticals, immunotherapies (e.g., vaccines), epigenetic agents, and theranostics, as well as novel combination and delivery platforms.

At ECRU we manage end-to-end drug development activities, including target discovery and validation, xenograft drug screening, clinical pharmacology, and biomarker-correlative clinical trials. Where appropriate, we perform sequential tumour biopsies to support longitudinal biomarker development.

Contact Us 

We have a variety of trials ongoing. For more information and to enquire about the availability of the trials, please email: clinical.trials@nccs.com.sg.